hrp0094p2-357 | Pituitary, neuroendocrinology and puberty | ESPE2021

Gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: a pharmacovigilance study in a pediatric population.

Nasso Chiara , Cafarella Giulia , Visalli Giulia , Di Prima Elena , Squadrito Violetta , Squadrito Francesco , Altavilla Domenica , Aversa Tommaso , Wasniewska Malgorzata , Valenzise Mariella ,

Background: Central precocious puberty (CPP) results from premature activation of hypothalamic-pituitary-gonadal axis, which leads to an increased release of gonadotropin-releasing hormone (GnRH). GnRH stimulates the development of secondary sexual features, rapid bone maturation and growth. GnRH agonists (GnRHa) represent the gold-standard therapy in CPP children and their use is responsible for pituitary GnRH receptors down-regulation, luteinizing hormone (L...